Claims
- 1. A compound of formula (I)
- 2. The compound according to claim 1, wherein R2 is a methyl group.
- 3. The compound according to claim 1, wherein X is Cl.
- 4. The compound according to claim 1, wherein n is equal to 2.
- 5. The compound according to claim 1, selected from the group consisting of:
3-[N-(3,5-dichlorophenyl)pyrrol-2-yl]-5-acetylaminoindolin-2-one 3-[N-(3-chlorophenyl)pyrrol-2-yl]-5-acetylaminoindolin-2-one, and 3-[N-(3,5-dichlorophenyl)pyrrol-2-yl]indolin-2-one-5-yl-N-methylcarboxamide.
- 6. A process of preparing a compound according to claim 1 comprising reacting a compound of formula (II)
- 7. The process according to claim 6, wherein said organic base is piperidine.
- 8. The process according to claim 6 wherein said protic solvent is ethanol.
- 9. The process according to claim 6 wherein said reaction temperature is the reflux temperature of the protic solvent.
- 10. A pharmaceutical composition, comprising a compound of claim 1 or a pharmacologically tolerable salt thereof and one or more physiologically acceptable excipients.
- 11. A method for the treatment of primary tumors of cancer comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound according to claim 1.
- 12. A method for the treatment of primary tumors of cancer comprising administering to a patient in need of said treatment a therapeutically effective tubulin polymerizaton into microtubules inhibiting amount of a compound according to claim 1.
- 13. A method for the treatment of primary tumors of cancer comprising administering to a patient in need of said treatment a therapeutically effective cell proliferation inhibiting amount of a compound according to claim 1.
- 14. A method for the treatment of primary tumors of cancer comprising administering to a patient in need of said treatment a therapeutically effective endothelial cells detaching amount of a compound according to claim 1.
- 15 A method for the treatment of primary tumors of cancer comprising administering to a patient in need of said treatment a therapeutically effective antivascular amount of a compound according to claim 1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
FR 01 03408 |
Mar 2001 |
FR |
|
Parent Case Info
[0001] This application is a continuation of International Application No. PCT/FR02/00852 filed Mar. 11, 2002, which claims the benefit of priority of French Application No.01/03408 filed Mar. 13, 2001
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/FR02/00852 |
Mar 2002 |
US |
Child |
10659094 |
Sep 2003 |
US |